Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021804 | 1.00 | SRD5A2 (0.55) | SRD5A2HSD11B1RARBRARGTP53 | |
| SCHEMBL14344210 | 0.88 | TSHR (0.46) | SRD5A2HSD11B1TSHREPHX2NR1H4 | |
| SCHEMBL9181746 | 0.88 | SRD5A2 (0.59) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL13917839 | 0.87 | SRD5A2 (0.63) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL17877682 | 0.84 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL16973856 | 0.83 | SRD5A2 (0.59) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL263313 | 0.83 | PTPN1 (0.59) | SRD5A2HSD11B1RARBRARG | |
| SCHEMBL1842933 | 0.83 | PTPN1 (0.59) | SRD5A2HSD11B1RARBRARG | |
| SCHEMBL10165226 | 0.82 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL18130711 | 0.82 | SRD5A2 (0.57) | SRD5A2RARBRARGTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772296-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1904435-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1904435-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2044004-B1 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2044004-B1 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2029540-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. | 2010-03-18 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006138508-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD17B1, HSD3B1, HSD11B1 | SRD5A2 28/4885HSD11B1 3/4885RARB 1969/4885 |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | SRD5A2 709/4885HSD11B1 1333/4885RARB 443/4885 |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD3B1, HSD17B1, HSD3B2 | SRD5A2 29/4885HSD11B1 4/4885RARB 1151/4885 |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | GPR119, GLP1R, UGT2B7 | SRD5A2 709/4885HSD11B1 1333/4885RARB 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.